drugset / Trial / NCT00839449
Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study
Phase 4
Completed
200 enrolled
Yamaguchi University Hospital
Iwate Medical University · collabNakamura Memorial Hospital · collabOotemachi Hospital · collabTohoku University · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
Cerebral vasospasm following subarachnoid hemorrhage (SAH) is the most common cause of morbidity and mortality. Recent studies indicate that Rho-kinase play an important role in the occurrence of such cerebral vasospasm. Eicosapentaenoic acid (EPA) inhibits sphingosylphosphorylcholine (SPC)-induced Rho-kinase activation in vitro. So this study examines whether EPA prevents cerebral vasospasm occurrence after SAH in patients.
Timeline
- Start
- 2004-12
- Primary completion
- 2008-06
- Completion
- 2008-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | icosapent ethyl | Small molecule | 900 mg | Oral |